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Abstract
Background: It is supposed that fibroblasts present in tumour microenvironment increase cancer invasiveness and
its ability to metastasize but the mechanisms have not been clearly defined yet. Thus, the current study was
designed to assess changes in gene expression in five various cancer cell lines grown as a co-culture with the
carcinoma-associated fibroblasts (CAFs) in vitro.
Results: A carcinoma-associated fibroblast cell line was isolated from a canine mammary cancer. Then, a co-culture
of cancer cells with the CAFs was established and maintained for 72 hrs. Having sorted the cells, a global gene
expression in cancer cells using DNA microarrays was examined. The analysis revealed an up-regulation of 100
genes and a down-regulation of 106 genes in the cancer cells grown as a co-culture with the CAFs in comparison
to control conditions. The PANTHER binomial statistics tool was applied to determine statistically over-manifested
pathways (p < 0.05). Bulk of the up-regulated genes are involved in the adhesion, the angiogenesis, the epithelial-
mesenchymal transition (EMT) and generally take part in the developmental processes. These results were further
confirmed using real-time qPCR. Moreover, a wound-healing assay and growth characteristics on Matrigel matrix
showed that CAFs increase cancer cell migration and matrix invasion.
Conclusion: The results of the current study showed that the co-culturing of cancer cells and the CAFs caused
significant changes to the cancer gene expression. The presence of the CAFs in a microenvironment of cancer cells
promotes adhesion, angiogenesis and EMT.
Background
Since canine mammary tumours in bulk are of epithelial
origin this kind of cells is subjected to many studies.
Over the last few years it has also been pin-pointed that
concomitant changes occur within stromal cells, which
contribute to the tumour microenvironment as well
[1,2]. Tumour microenvironment embraces inflamma-
tory, fibroblastic, endothelial cells, adipocytes and other.
Changes within these stromal cells have been postulated
to increase the tumorigenic phenotype of the epithelial
cell, promote malignant transformation, induce epithe-
lial-mesenchymal transition (EMT) and promote tumour
spreading and metastasis [3]. It is worth noting however,
that in almost all the tumours, the main cell type of
cancer stromal compartment is fibroblast. These cells
are usually atypical and are termed carcinoma-associated
fibroblasts (CAFs). We assume there is a cross-talk
between the tumour cells and the CAFs, which pro-
motes migratory, and invasive properties of cancer cells
[3] though their exact role within cancer microenviron-
ment has not been fully defined yet. Thus, the study
was conducted to assess the changes in gene expression
in cancer cells grown as a co-culture with the CAFs in
vitro. As far as we know the study presented hereby is a
pioneering microarray experiment in this field. Despite
that our study involved five various cell lines, only one
CAFs cell line was used, thus the results may be limited
to this particular CAF model. Further studies in this
field are required.
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any medium, provided the original work is properly cited.The analysis revealed an up-regulation within a span
of 100 genes and a down-regulation within 106 genes in
cancer cells grown as a co-culture with the CAFs, com-
paring against set control conditions. In this manuscript
we focused mainly on the gene sets involved in adhe-
sion, developmental process and neurotransmissions.
The results of our study can be extrapolated on human
research because canine mammary tumours are being
considered a spontaneous animal model of human breast
cancer [4]. There are many similarities between human
and canine mammary cancers: in both species they repre-
sent a heterogeneous group in terms of morphology and
biological behaviour [5], in both similar cancer-related
pathways are activated [6-8] as much as both species live
under similar environmental conditions.
Methods
Cell lines
The cell lines used for this study have previously been
given an account of [9-12]. Two canine mammary ade-
nocarcinoma cell lines (CMT-W1, CMT-W2), an ana-
plastic cancer cell line (P114), a simple carcinoma cell
line (CMT-U27) and a spindle-cell mammary tumour
cell line (CMT-U309) were examined. The CMT-W1
and the CMT-W2 cell lines had kindly been donated by
Prof. Dr. Maciej Ugorski and Dr. Joanna Polanska from
Wroclaw University of Environmental and Life Sciences
(Poland). The CMT-U27 cell line had kindly been
donated by Dr. Eva Hellmen from Swedish University of
Agricultural Sciences (Sweden) and the P114 cell line
had kindly been donated by Dr. Gerard Rutteman from
Utrecht University (The Netherlands).
The cells were cultured under optimal conditions: a
medium (RPMI-1640) enriched with 10% (v/v) heat-
inactivated fetal bovine serum (FBS), penicillin-strepto-
mycin (50 iU mL-1), and fungizone (2.5 mg mL-1)
(reagents obtained from Sigma Aldrich, USA), in an
atmosphere of 5% CO2 and 95% humidified air at 37°C,
and routinely sub-cultured every other day. The meth-
ods of canine mammary cancer cells culturing have pre-
viously been given an account of [9-12].
Tumour sample
A mammary tumour was surgically removed during
mastectomy on a 12 years old mixed breeds female. The
tumour then, was divided into equal halves, one of them
was fixed in 10% neutral buffered formalin and routinely
embedded in paraffin to perform histological assay. The
other, was used to isolate and establish a carcinoma-
associated fibroblast cell line.
Carcinoma-associated fibroblasts isolation
The cells isolation from cancer tissue has been described
in our previous manuscript [13]. The tumor sample was
collected into the medium RPMI 1640 (Sigma Aldrich,
USA) containing flask immediately after mastectomy.
The RPMI 1640 medium had been used to maintain the
same culturing conditions for mono- and co-culture.
The tumour sample was then sliced and cultured over-
night in collagenase containing medium RPMI 1640
according to the Limon et al. [14] protocol (modified by
Dr Eva Hellmen, Swedish University of Agricultural
Sciences, Sweden). The following day, the medium was
centrifuged and pellet was suspended in a fresh culture
medium supplemented in FGF (10 nM/ml, obtained
from Sigma Aldrich, USA), a medium that encourages
preferential fibroblastic outgrowth.
Histopathological examination
The tissue sample embedded in paraffin block was cut
into five μm sections and baked in 37°C overnight. After
dewaxing in xylene and rehydration in ethanol, for anti-
gen retrieval, the slides were placed in 0.02 M citrate
buffer, pH 6.0 and boiled in the decloaking chamber.
The tumor type was classified based on the World
Health Organization (WHO) Histological Classification
and Mammary Tumors of the Dog and Cat classification
[15,16]. The mammary carcinoma grading was assessed
in respect to tubule formation, degree of differentiation
and mitotic index.
The carcinoma-associated fibroblasts and the canine
mammary cancer cells were cultured on Lab-Tek (Nunc
Inc., USA) 4-chamber culture slides and were then fixed
with ethanol after the 24 hrs.
The immunohistochemical examination of expression
of Ki67, cytokeratin, vimentin, smooth muscle actin,
s100 protein, p63 protein was performed on the tissue
sample as well as on carcinoma-associated fibroblasts to
confirm the origin of cell culture. The MUC1 expression
was analyzed in the canine mammary cancer cell lines.
The samples were incubated in the Peroxidase Block-
ing Reagent (Dako, Denmark) for 10 min at room tem-
perature prior to the antibody incubation. After 30 min
incubation in 5% bovine serum albumin (Sigma Aldrich,
Germany), the following primary antibodies were used
(diluted in 1% bovine serum): mouse monoclonal anti-
Ki67 (Clone MIB-1) at the concentration 1:75; monoclo-
nal mouse anti-human cytokeratin (Clone MNF116) at
the concentration 1:50; monoclonal mouse anti-human
vimentin (Clone Vim 3B4) at the concentration 1:50;
monoclonal mouse anti-human actin (Clone HHF35) at
the concentration 1:50; polyclonal rabbit anti-S100
(ready to use solution) all obtained from Dako (Den-
mark); monoclonal mouse anti-p63 protein (Santa Cruz
Biotechnology, USA) and monoclonal mouse anti-
MUC1 (Abcam, United Kindgdom) at the concentration
1:10. According to the manufacturer’si n s t r u c t i o n st h e
slides were incubated with antibodies at +4°C overnight
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mouse or anti-rabbit EnVision kits (Labelled Polymers
consist of secondary anti-rabbit antibodies conjugated
with the HRP enzyme complex obtained from Dako)
were used. To develop the coloured product, the 3,3’-
Diaminobenzidine (DAB) substrate was used (Dako).
Finally, the haematoxylin was used for nuclei
counterstaining.
For each immunohistochemical analysis as the nega-
tive control, the staining without the use of primary
antibodies was done. The pictures were taken using
Olympus microscopy BX60 (Olympus, Germany).
Co-culture and sorting
The CAFs (10
5 cells) were grown on 75 cm
2 culture
flasks and the cancer cells (CMT-W1, CMT-W2, CMT-
U27, CMT-U309, P114) were layered (5 × 10
5 cells) on
the top of the CAFs (fibroblasts and cancer cells at 1:5
ratio [17]). An Orange CellTracker fluorescent dye
CMTMR (Invitrogen, USA) was used to stain the CAFs’
population before the cancer cell population was added.
Initially, optimal staining conditions were determined by
incubating CAFs in various concentrations of CMTMR
(5-25 μM dye, according to the manufacturer’si n s t r u c -
tions) and checking the fluorescence signal after 72 hrs
using FACS. The lowest concentration that gives posi-
tive results has been used in further experiments (5
μM). Staining was accomplished by incubation in
serum/antibiotics-free RPMI medium containing 5 μM
CMTMR (10 mM stock in DMSO; Sigma Aldrich, USA)
for 45 min at 37°C. Subsequently, the medium was aspi-
rated, and the CAFs were washed with PBS twice and
incubated with complete RPMI for 1 hr and then again
washed to remove any remnant non-metabolized
CMTMR. The cancer cells were placed on the
CMTMR-stained CAFs.
The co-culture was maintained for 72 hrs. Then, the
cells were harvested by trypsynization, analyzed and
sorted using FACS Aria II high speed cell sorter with
Diva 5.0 software (Becton Dickinson, USA). Based on
the FSC and SSC cytogram, live cells were gated to
exclude all dead cells, cell debris and cell clumps.
Within the gated cell populations, fluorescing cells were
identified as CMTMR-labelled carcinoma-associated
fibroblasts and non-fluorescent as cancer cells. Excita-
tion wavelength used was 488 nm, whereas emission
wavelength used was 578 nm. Cancer cells were sorted
into RPMI 1640 medium in 15 ml polypropylene tubes
(BD Biosciences).
Confocal microscopy
The CAFs grown as a mono-culture were stained using
Orange CellTracker fluorescent dye CMTMR, as
described above. The cells grown on plastic were fixed
in 70% ethanol (10 min), washed in PBS three times and
the coverslips were mounted on microscope slides using
ICN mounting medium. The cell imaging was per-
formed on confocal laser scanning microscope FV-500
system (Olympus Optical Co, Germany) after 1 hr, then
after 72 hrs after the staining. The excitation/emission
were: HeNe 543 nm laser with 610 nm filter for
CMTMR staining. The cells were examined using the
Fluoview program (Olympus Optical Co., Germany).
The pictures have been analyzed using a computer-
assisted image analyzer (Olympus Microimage™ Image
Analysis, software version 4.0 for Windows, USA).
Wound-healing assay
To assess the migration ability of cancer cells grown as
a co-culture with CAFs, we applied a wound-healing
test. The cancer cells (grown as the co-culture with
CAFs at the 5:1 ratio, and normal control cells) were
separately seeded in multi-well plates and then, (after 72
hrs when the cells were confluent) using a pipette tip
(100 ul) a straight scratch had been made, simulating a
wound. The images were captured at the beginning and
at regular intervals (after 2, 4 and 6 hours) during cell
migration to close the wound. The images then were
compared to quantify the cells’ migration rate. This
method is particularly suitable for studies of cell-cell
interaction on cell migration [18]. The pictures have
been analyzed using a computer-assisted image analyzer
(Olympus Microimage™ Image Analysis, software ver-
sion 4.0 for Windows, USA).
3D culture
Cancer cells were treated with trypsin and resuspended
in culture medium. 35 mm culture plates (Corning Inc.)
were coated with 100 μl of growth factor reduced Matri-
gel (BD Biosciences) and left to solidify for 30 min. at
37°C. The control cells were then plated at a concentra-
tion of 10
4 cells/ml. Co-cultured cells were plated at the
same concentration (cancer cells and CAFs at 5:1 ratio).
The growth of cells on Matrigel was observed everyday
under phase-contrast microscope (Olympus).
Microarray analysis
The sorted cancer cells grown as a co-culture were cen-
trifuged (2,500 rpm for 5 min), whereas cancer cells
grown as mono-cultures were washed with PBS and har-
vested by trypsynization and centrifuged (2,500 rpm for
5 min). The total RNA from the samples was isolated
using a Total RNA kit (A&A Biotechnology, Poland)
according to the manufacturer’s protocol. The isolated
RNA samples were dissolved in RNase-free water. The
quantity of the isolated RNA was measured using Nano-
Drop (NanoDrop Technologies, USA). The samples with
adequate amounts of RNA were treated with DNaseI to
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quently purified using RNeasy MiniElute Cleanup Kit
(Qiagen, Germany). Finally the RNA samples were ana-
lyzed on a BioAnalyzer (Agilent, USA) to measure the
final RNA quality and integrity.
The total RNA (10 μg) of each cell line was reverse-
transcribed using SuperScript Plus Direct cDNA Label-
ing System, (Invitrogen, USA) according to the manu-
facturer’s protocol for each microarray slide. Single-
strand cDNAs were stained with Alexa 647 and Alexa
555 (Invitrogen). Dog-specific oligonucleotide microar-
ray slides Canis familiaris V1.0.1 AROS (Operon, USA)
with 25,383 probes were used for the hybrydization.
Hybridization was performed using automatic hybridiza-
tion station HybArray12 (PerkinElmer, USA). Two repli-
cates were made (dye-swap).
The slides were analyzed using microarray scanner
ScanArray HT and ScanExpress software (PerkinElmer,
USA).
Real-time qPCR
The mRNA sequences of the key genes were obtained
from NCBI database. Primers were designed using PRI-
MER3 software (free on-line access) and checked using
Oligo Calculator (free on-line access) and Primer-Blast
(NCBI database). Primers’ sequences are listed in Table
1. HPRT and RPS19 genes were used as non-regulated
reference genes for normalization of target gene expres-
sion [19,20]. Quantitative RT-PCR was performed using
fluorogenic Lightcycler Fast Strand DNA Sybr Green
(Roche) and the Light Cycler (Roche). The results were
analyzed using comparative Ct method [21]. Relative
transcript abundance of the gene equals ΔCt values
(ΔCt = Ct
reference -C t
target). Relative changes in tran-
script are expressed as ΔΔCt values (ΔΔCt = ΔCt
co-cul-
ture - ΔCt
control). The experiment was conducted three
times.
Statistical analysis
In the analysis of differential gene expression, back-
ground-corrected value of signal in each microarray
channel was used. Prior to the analysis, non-specific
filtering was performed, i.e. genes with small level of
expression were removed (we set an arbitrary threshold
according to which at least half of the samples’ expres-
sion was to be at least 100). This reduced the number
of genes down to 24 842. Then the log2 ratio of the
sample vs control channels was calculated and the signal
was loes normalized. Quality control, including MA ana-
lysis, and signal normalization were done with the Bio-
conductor software. The analysis of differential
expression was performed using linear methods for
microarrays (limma package in Bioconductor software)
[22]. The method tests the null hypothesis of no differ-
ential expression between the sample and control
groups using the moderated t-statistic [22], which has
similar interpretation as the ordinary t-test statistic. We
identified 206 genes with the p-value below 0.05 and
fold change > 2.0.
The microarray data discussed in this publication has
been deposited in NCBI’sG e n eE x p r e s s i o nO m n i b u s
and is freely accessible through GEO Series accession
number GSE29601.
The gene function was identified using the NCBI data-
base and PANTHER pathway analysis software [23]. The
pathway analyses were conducted using binominal sta-
tistic test (PANTHER) with the cut-off value p < 0.05.
The statistical analysis of optical density, wound heal-
ing assay and Real-time qPCR was conducted using
Prism version 5.00 software (GraphPad Software, USA).
The one-way ANOVA, and ANOVA + Tukey HSD
(Honestly Significant Difference) post-hoc test as well as
t-test were applied. The p-value < 0.05 was regarded as
significant whereas p-value < 0.01 and p-value < 0.001
as highly significant.
Results
Tumor sample and CAFs examination
The histopathological and immunohistochemical assess-
ment of the tissue sample, from which the carcinoma-
associated fibroblasts were isolated, showed that the
tumour type was a complex carcinoma of the 1
st grade
malignancy (Figure 1a). The histopathological and
immunohistochemical analysis of the isolated cells
Table 1 Primers used for Real-time qPCR
Gene symbol Forward primer Reverse primer Optimum annealing temp. (°C) Optimum annealing time (sec)
DSP CAGACTCACCGAAGAGGAAA CTGCTGTGAAGTCTGGGAGT 61 7
MAG TGCCATCGTCTGCTACATTA CAGTCGCCTCTCACTCTCAT 60 6
PCDH19 CTTTCACATCACTGCACTCG GTGTGTTGGGAGGTGAGTTC 61 6
HPRT AGCTTGCTGGTGAAAAGGAC TTATAGTCAAGGGCATATCC 59 6
RPS19 CCTTCCTCAAAAAGTCTGGG GTTCTCATCGTAGGGAGCAAG 61 10
Primers sequences used in this study and their annealing optimal temperature and time. The mRNA sequences of key genes were obtained from NCBI database.
Primers were designed using PRIMER3 software (free on-line access) and checked using Oligo Calculator (free on-line access) and Primer-Blast (NCBI database).
HPRT and RPS19 genes were used as non-regulated reference genes for normalization of target gene expression [19,20].
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cytokeratin, S100 protein, p63 protein and actin,
whereas a strong vimentin expression was detected (at
the level of 3 in 0-3 scale) (Figure 1c). The analysis con-
firmed that the isolated cell line is an atypical colony of
fibroblasts which are termed the CAFs.
Sorting of the co-cultured cells
The Flow-Cytometry easily distinguished the CMTMR-
stained cells from the unstained ones (Figure 2a) and
allowed the proper further sorting of each population
(Figure 2b, c). The co-culture was maintained for 72 hrs.
According to the manufacturer’s instruction, CMTMR
probes remain vividly fluorescent for at least 72 hrs after
incubation in fresh medium at 37°C and through at least
four cell divisions. The confocal observations confirmed
that after 72 hrs of the staining with the CMTMR all the
cells showed red-staining cytoplasm pattern (Figure 2c, d,
e). No detrimental effects on proliferation and plating
efficiency was observed. Our analysis of optical density of
the red dye in the cells measured 1 hr and 72 hrs after
the staining showed very similar results (any statistically
s i g n i f i c a n td i f f e r e n c eh a dn o tb e e nf o u n d )( F i g u r e2 f ) .I t
indicates that there wasn’t any staining loss, thus we sup-
pose that the dye wasn’t leaking from CAFs to stain can-
cer cells. It had been also suggested in the subject
literature [24]. Moreover, confocal microscopy analysis of
the red dye fluorescence with Nomarski Interferenced
Contrast showed that all of the stained CAFs maintained
their staining pattern after the 72 hrs. Thus, the artificial
sorting of unstained CAFs as cancer cells is not very
probable. Our FACS sorting isolated a 97-99% pure
population on postsort (assessed by BC FACS Diva 5.0
software) what was checked by FACS (Figure 2b, c) and
fluorescence microscopy (data not shown). Previously
published study of the human fibroblasts and epithelial
cells sorting based on the cell tracker staining showed
similar results [25].
Migration assay and growth characteristics on Matrigel
matrix
The wound healing assay showed that in all the cancer
cell lines the co-culturing with CAFs increased their
migratory abilities (Figure 3). CMT-U27 cells grown
with CAFs almost completely closed the wound (99%)
in 6 hours, whereas CMT-U27 control cells after 6 hrs
closed 68% of the wound. Similarly, CMT-U309 and
P114 cells (grown with CAFs) after 6 hrs completely
closed the wound (100%), whereas control cells closed
only 55% and 50% (respectively) of the wound. CMT-
W1 cells grown with CAFs completely closed the
wound after 4 hrs, whereas CMT-W1 control cells after
6h r s( a f t e r4h r s6 4 %o ft h ew o u n dw a sc l o s e d ) .C M T -
W2 cells grown with CAFs closed 93% of the wound
after 6 hrs, whereas control cells closed only 52% of the
wound.
To assess the ability of the cell lines to matrix inva-
sion, we have assessed their growth characteristics on
Matrigel matrix (Figure 4). After 72 hrs of culturing
(similarly as in all experiments) on Matrigel CMT-U27,
CMT-U309 and P114 cell lines formed colonies,
whereas CMT-W1 and CMT-W2 cell lines formed
branching structures (Figure 4a) what indicated their
invasive phenotype. However, all the cell lines grown as
a co-culture with CAFs after 72 hrs were dispersed (Fig-
ure 4b) what indicated increase of their matrix invasion
ability by CAFs.
Gene expression analysis
The gene expression analysis showed similar rate of
gene expression in each of the dye-swap experiment.
This result indicates that all microarray samples were
successfully labeled, hybridized, and scanned. The discri-
minating analysis (with p value cut-off < 0.05; fold
change > 2.0) revealed 106 up-regulated (Table 2) and
100 down-regulated (Table 3) genes in cancer cells
grown as a co-culture with the CAFs in each of the
Figure 1 Cancer associated fibroblasts isolated from canine mammary cancer. Representative pictures of A. Canine mammary complex
carcinoma (HE staining) tissue from which the carcinoma-associated fibroblasts were isolated. B. The culture of carcinoma-associated fibroblasts
(CAFs) isolated from the canine mammary complex carcinoma (HE staining) and C. Carcinoma-associated fibroblasts (CAFs) isolated from canine
complex mammary carcinoma revealed a strong vimentin expression (brown color). The pictures were obtained using Olympus BX60
microscope (at the magnification of 200×).
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for each cell line examined individually, compared to
the same cell line grown as a mono-culture. Thus, these
genes were activated/inactivated in all of the cell lines
under co-culture conditions with the CAFs.
The PANTHER binomial statistics tool to compare
classifications of multiple clusters of lists to a reference
list of Canis familiaris genes allowed us to statistically
determine over-manifestation of PANTHER biological
process and pathways classification categories. The
PANTHER biological process analysis revealed that
most of the up-regulated genes in cancer cells grown as
a co-culture with the CAFs were involved in: cell surface
receptor linked signal transduction (p = 9.05E-03), lyso-
somal transport (p = 9.2E-03), developmental process (p
= 3.64E-02), antigen processing and presentation (p =
4.22E-02), signal transduction (p = 4.35E-02), cell com-
munication (p = 4.55E-02), nervous system development
(p = 4.97E-02).
Because our concern involved interactions between
cancer cells and carcinoma associated fibroblasts which
could predispose cancer to metastasis, we specifically
focused on the up-regulated genes involved in cell adhe-
sion and cellular morphogenesis: QRICH2, CHAD,
Figure 2 Histogram and pictures of unstained cancer cells and stained CAFs. A. Representative histogram and sorting gates of unstained
cancer cells and CMTMR-stained carcinoma-associated fibroblasts (CAFs) grown as the co-culture for 72 hrs. B. Histogram of cancer cells sorted
from co-culture showing only CMTMR-negative cells. C. Histogram of CAFs sorted from co-culture showing only CMTMR-positive cells. D. and E.
Representative pictures obtained using confocal microscopy showing red-colored stained cytoplasm (CMTMR staining) of CAFs growing as a
single culture for 1 hr and 72 hrs, respectively. The imaging of cells was performed on confocal laser scanning microscope FV-500 system
(Olympus Optical Co, Germany). The cells were examined using the Fluoview program (Olympus Optical Co., Germany). F. The graph showing
mean optical density of the red (reflecting CMTMR staining) in CAFs at 1 hr and 72 hrs after staining. For statistical purposes the t-test has been
applied (Graph Pad 5.0), no significant difference has been observed between these two values.
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LPHN2, DSP, KTN1, VCAM1, MAG, and PTPN6
(Table 2). Interestingly, the gene expression analysis also
revealed an up-regulation of 24 genes involved in devel-
opmental processes such as: a mammary gland develop-
ment, a mesoderm development, an ectoderm
development, a skeletal system development, a nervous
system development, an embryonic development, a
heart development, and a muscle-organ development.
The pathway analysis revealed that significantly over-
manifested were: the salvage pyrimidine ribonucleotides
(p = 02.87E-03), the oxytocin receptor mediated signal-
ing pathway (p = 4.76E-03), the thyrotropin-releasing
hormone receptor signaling (p = 5.21E-03), the 5HT2
type receptor mediated signaling pathway (p = 6.99E-
03), the metabotropic glutamate receptor III (p = 8.14E-
03), the metabotropic glutamate receptor group II (p =
3.33E-02), the metabotropic glutamate receptor I (p =
1.75E-02), the Beta 2 and Beta1 adrenergic receptor sig-
naling (p = 2.54E-02) and the histamine H1 receptor
mediated signaling (p = 2.87E-02).
Among the down-regulated genes no significant path-
ways or biological processes and their over-manifesta-
tion were found (Table 3) comparing to a reference list
of Canis familiaris genes.
The results were confirmed at mRNA level using real-time
qPCR analysis
For the purposes of the microarray data validation, we
have randomly selected 3 of all the genes that may play
Figure 3 Wound healing assay of canine mammary cancer cells grown in control conditions and as a co-culture with CAFs.A
Representative pictures of migration (wound closing) of CMT-U309 cell line grown as a mono-culture and co-culture with CAFs at 0, 2, 4 and 6
hrs after the scratch was made. B The graphs of % of wound closure after the 2, 4 and 6 hrs of migration. The pictures were taken using phase-
contrast microscopy (Olympus) at the magnification of 100×. The statistical analysis was performed using Prism version 5.00 software (GraphPad
Software, USA). The one-way ANOVA was applied to analyze the results. p < 0.05 was regarded as significant and marked as *, whereas p < 0.01
and p < 0.001 were regarded as highly significant and marked as ** and ***, respectively.
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tions: PCDH19, DSP and MAG. Real-time qPCR results
showed similar trends in gene expression changes as were
observed in microarray studies (Figure 5).
MUC1 expression detection in cancer cell lines
Because the MAG gene up-regulation was found in can-
cer cells grown as a co-culture with the CAFs, the
expression of MUC1 (which binds MAG) was examined
immunohistochemically (Figure 6). The MUC1 expres-
sion was confirmed in all of the examined cell lines.
Discussion
Canine mammary cancers in bulk arise from epithelial
cells. Several genetic alterations have been detected, that
may predispose these cells to the malignant transforma-
tion [10-12]. However, researches over the last few years
suggested that concomitant changes also occur in stro-
mal cells that form the tumour microenvironment [1,2].
The hypothesis of stromal cells involvement in tumori-
genesis is based on a study of embryological develop-
ment where interactions between various cells are
necessary for programming and maintaining epithelial
structure and function. The embryonic epithelial and
stromal cells of mesenchymal origin engage in a mole-
cular dialogue that ensures the proper organ develop-
ment and function [3].
The study showed in cancer cells after a co-culture
with CAFs an up-regulation of 23 genes (Table 2)
involved in developmental processes (a nervous system
development, an embryonic development, a mesoderm
and ectoderm development).
The involvement of fibroblasts in the malignant trans-
formation of epithelial cells has previously been docu-
mented [3,26-28]. Moreover, the histology and growth
characteristics of CAFs were found different from those
of the fibroblasts associated with normal epithelial cells
[3]. Mishra et al. [29] have proposed bidirectional cross-
talk between the CAFs and the cancer cells which
release proteins that increase the fibroblasts ability to
secrete a variety of tumour-promoting factors, which
then act back on the malignant cells to change their
gene expression and promote their proliferative, migra-
tory, and invasive properties. On the other hand, other
studies showed that only direct contact of fibroblasts
with cancer cells is able to cause changes in their gene
expression and biology [30-32].
So far several papers have been published about gene
expression in tumour microenvironment. Most of them
describe gene expression in fibroblasts, but not in can-
cer cells, however there are some papers available about
the changes in gene expression in cancer cells [33-36].
These reports indicated up-regulation of genes involved
in angiogenesis, EMT and migration in cancer cells
grown with fibroblasts. Surprisingly, some of the genes
identified, even though functionally identical turned out
to be of different names. The studies have been con-
ducted using various cancer models (various species)
and various cell lines, so the differences are possible.
Figure 4 Canine mammary cancer cell lines growth
characteristics in Matrigel matrix. A Growth characteristics of
CMT-U27, CMT-U309, P114, CMT-W1 and CMT-W2 cell lines (phase
contrast micrographs) grown on Matrigel matrix for 72 hours. B
Growth characteristics of CMT-U27, CMT-U309, P114, CMT-W1 and
CMT-W2 cell lines (phase contrast micrographs) grown as a co-
culture with CAFs on Matrigel matrix for 72 hours. The pictures
were taken using phase-contrast microscopy (Olympus) at the
magnification of 200×.
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No Fold
change
Gene ID Gene name Molecular function Biological process
1 4.18 TRIM6 Tripartite motif-containing
protein 6
ubiquitin-protein ligase activity; structural
constituent of cytoskeleton; RNA binding;
cytoskeletal protein binding
spermatogenesis; neurotransmitter secretion;
intracellular protein transport; exocytosis; cell
cycle; signal transduction; synaptic
transmission; carbohydrate metabolic
process; protein metabolic process; cell-cell
signaling; dorsal/ventral axis specification;
mesoderm development; mammary gland
development
2 3.76 PPP1R12A Protein phosphatase 1
regulatory subunit 12A
protein binding; phosphatase regulator
activity
protein metabolic process
3 3.73 TCHHL1 Trichohyalin-like protein 1
4 3.24 QRICH2 Glutamine-rich protein 2 receptor activity fertilization; cell adhesion
5 3.14 TMEM82 Transmembrane protein 82
6 3.14 ZNF212 Zinc finger protein 212 DNA binding; transcription factor activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
7 3.13 PYROXD1 Pyridine nucleotide-
disulfide oxidoreductase
domain-containing protein
1
oxidoreductase activity immune system process; respiratory electron
transport chain; apoptosis; ferredoxin
metabolic process; oxygen and reactive
oxygen species metabolic process
8 3.10 PDE5A cGMP-specific 3’,5’-cyclic
phosphodiesterase
hydrolase activity, acting on ester bonds visual perception; sensory perception; signal
transduction; nucleobase, nucleoside,
nucleotide and nucleic acid metabolic
process; signal transduction
9 3.02 CHAD Chondroadherin receptor activity immune system process; cell surface
receptor linked signal transduction; cell-cell
adhesion; mesoderm development; skeletal
system development
10 3.00 QSER1 Glutamine and serine-rich
protein 1
11 2.96 PRKX Serine/threonine-protein
kinase
kinase activity muscle contraction; neurological system
process; mitosis; intracellular signaling
cascade; protein metabolic process; signal
transduction;
12 2.90 ZFAND5 AN1-type zinc finger
protein 5
nucleic acid binding sensory perception; respiratory electron
transport chain
13 2.86 C2CD3 C2 domain-containing
protein 3
14 2.82 CEP110 Centriolin;Centrosomal
protein of 110 kDa
15 2.80 FOXQ1 Forkhead box protein Q1 DNA binding; transcription factor activity visual perception; sensory perception; cell
cycle; cell surface receptor linked signal
transduction; carbohydrate metabolic
process; nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process; cellular
component morphogenesis; segment
specification; anterior/posterior axis
specification; ectoderm development;
mesoderm development; embryonic
development; nervous system development
16 2.80 NUP210L Nuclear pore membrane
glycoprotein 210-like
intracellular protein transport; nuclear
transport
17 2.79 SLC22A11 Solute carrier family 22
member 11
ATPase activity, coupled to transmembrane
movement of substances; ligase activity;
carbohydrate transmembrane transporter
activity; cation transmembrane transporter
activity
cation transport; anion transport; extracellular
transport; carbohydrate transport;
carbohydrate metabolic process
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18 2.78 HERC2 Probable E3 ubiquitin-
protein ligase HERC2
ubiquitin-protein ligase activity protein metabolic process; ectoderm
development; mesoderm development;
skeletal system development; nervous
system development
19 2.76 PCSK6 Proprotein convertase
subtilisin/kexin type 6
peptidase activity cell surface receptor linked signal
transduction; cell-matrix adhesion; protein
metabolic process; signal transduction;
mesoderm development
20 2.76 UCK2 Uridine-cytidine kinase 2 kinase activity; transferase activity,
transferring glycosyl groups
carbohydrate metabolic process; nucleobase,
nucleoside, nucleotide and nucleic acid
metabolic process
21 2.76 WFDC5 WAP four-disulfide core
domain protein 5
protein binding;peptidase inhibitor activity protein metabolic process
22 2.75 RPS10 40S ribosomal protein S10 structural constituent of ribosome; nucleic
acid binding
protein metabolic process
23 2.75 SLC7A14 Probable cationic amino
acid transporter
amino acid transmembrane transporter
activity; transmembrane transporter activity
amino acid transport; cellular amino acid
and derivative metabolic process
24 2.75 UBQLN2 Ubiquilin-2;UBQLN2 protein metabolic process
25 2.70 CLEC7A C-type lectin domain family
7 member A
receptor activity; receptor binding B cell mediated immunity; natural killer cell
activation; intracellular protein transport;
endocytosis; signal transduction; cell-cell
adhesion; signal transduction; cellular
defense response
26 2.70 SH3BP1 SH3 domain-binding
protein 1
protein binding; small GTPase regulator
activity
cell surface receptor linked signal
transduction; signal transduction; cellular
component morphogenesis
27 2.68 HMGB2 High mobility group
protein B2
DNA binding; chromatin binding; receptor
binding; transcription factor activity
intracellular signaling cascade; nucleobase,
nucleoside, nucleotide and nucleic acid
metabolic process; signal transduction;
organelle organization; establishment or
maintenance of chromatin architecture
28 2.68 TMSB10 Thymosin beta-10
29 2.67 NEFM Neurofilament medium
polypeptide
structural constituent of cytoskeleton cellular component morphogenesis;
ectoderm development
30 2.67 ZNF274 Zinc finger protein 274 DNA binding;transcription factor activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
31 2.66 PCDH19 Protocadherin-19 G-protein coupled receptor activity; calcium
ion binding
cell surface receptor linked signal
transduction; cell-cell adhesion; cell motion;
signal transduction; cellular component
morphogenesis; ectoderm development;
mesoderm development; embryonic
development; nervous system development;
heart development; muscle organ
development
32 2.61 KCMF1 E3 ubiquitin-protein ligase
KCMF1
33 2.60 PIP4K2B Phosphatidylinositol-5-
phosphate 4-kinase type-2
beta
kinase activity cell surface receptor linked signal
transduction; lipid metabolic process; signal
transduction
34 2.57 GNAT3 Guanine nucleotide-
binding protein G(t)
subunit alpha-3
GTPase activity; protein binding cell surface receptor linked signal
transduction; signal transduction
35 2.56 LPCAT1 1-
acylglycerophosphocholine
O-acyltransferase 1
acyltransferase activity; calcium ion binding;
calmodulin binding; calcium-dependent
phospholipid binding
metabolic process
36 2.56 XPR1 Xenotropic and polytropic
retrovirus receptor 1
G-protein coupled receptor activity cell surface receptor linked signal
transduction; signal transduction; embryonic
development
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37 2.54 LPHN2 Latrophilin-2 G-protein coupled receptor activity immune system process; neurotransmitter
secretion; intracellular protein transport;
exocytosis; cell surface receptor linked signal
transduction; synaptic transmission; cell
adhesion; cell-cell signaling; mesoderm
development; angiogenesis; heart
development
38 2.54 MPHOSPH6 M-phase phosphoprotein 6 cell cycle
39 2.52 NDUFB10 NADH dehydrogenase
[ubiquinone] 1 beta
subcomplex subunit 10
oxidoreductase activity oxidative phosphorylation; respiratory
electron transport chain
40 2.51 DSP Desmoplakin structural constituent of cytoskeleton;
cytoskeletal protein binding
cell adhesion; cellular component
morphogenesis; ectoderm development
41 2.51 EXOC3L2 Exocyst complex
component 3-like protein 2
spermatogenesis; immune response;
macrophage activation; intracellular protein
transport; exocytosis; mesoderm
development; angiogenesis; hemopoiesis;
response to stimulus
42 2.50 UBXN1 UBX domain-containing
protein 1
43 2.49 MYOT Myotilin;
44 2.49 SHPRH E3 ubiquitin-protein ligase DNA helicase activity; nucleic acid binding nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; organelle
organization; establishment or maintenance
of chromatin architecture
45 2.49 SMYD1 SET and MYND domain-
containing protein 1
DNA binding; transcription factor activity;
transcription cofactor activity
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
46 2.48 KTN1 Kinectin structural constituent of cytoskeleton intracellular protein transport; cellular
component morphogenesis
47 2.48 PJA2 E3 ubiquitin-protein ligase
Praja2
DNA binding; transcription factor activity
48 2.48 SRPK1 Serine/threonine-protein
kinase SRPK1
kinase activity immune system process; mitosis; cell surface
receptor linked signal transduction;
intracellular signaling cascade; carbohydrate
metabolic process; protein metabolic
process; cell motion; mitosis; signal
transduction; segment specification;
ectoderm development; mesoderm
development; embryonic development;
nervous system development; response to
stress
49 2.47 ANKS3 Ankyrin repeat and SAM
domain-containing protein
3
50 2.47 C20orf26 Uncharacterized protein
C20orf26
51 2.47 TREML2 Trem-like transcript 2
protein
52 2.46 TAB2 Mitogen-activated protein
kinase kinase kinase 7-
interacting protein 2
DNA binding; transcription factor activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
53 2.45 C19orf6 Membralin structural molecule activity
54 2.45 EPB41L2 Band 4.1-like protein 2
55 2.44 CCDC71 Coiled-coil domain-
containing protein 71
56 2.44 FGD1 FYVE, RhoGEF and PH
domain-containing protein
1
protein binding; small GTPase regulator
activity; guanyl-nucleotide exchange factor
activity
mesoderm development; skeletal system
development
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57 2.44 VCAM1 Vascular cell adhesion
protein 1
hydrolase activity, acting on ester bonds;
phosphatase activity; receptor activity
immune system process; muscle contraction;
induction of apoptosis; cell cycle; cell surface
receptor linked signal transduction; cell-cell
signaling; cell-cell adhesion; protein
metabolic process; cell motion; cell cycle;
signal transduction; ectoderm development;
mesoderm development; angiogenesis;
nervous system development; muscle organ
development
58 2.42 ANKRA2 Ankyrin repeat family A
protein 2
DNA binding; transcription factor activity antigen processing and presentation of
peptide or polysaccharide antigen via MHC
class II; cellular defense response
59 2.42 KCNK17 Potassium channel
subfamily K member 17
cation transmembrane transporter activity;
voltage-gated potassium channel activity;
cation channel activity
neurological system process; cation transport
60 2.42 TXNDC15 Thioredoxin domain-
containing protein 15
61 2.41 TBPL2 TATA box-binding protein-
like protein 2
DNA binding; transcription factor activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
62 2.40 ALDH3A2 Fatty aldehyde
dehydrogenase
oxidoreductase activity carbohydrate metabolic process; nucleobase,
nucleoside, nucleotide and nucleic acid
metabolic process; cellular amino acid and
derivative metabolic process
63 2.40 LAMP3 Lysosome-associated
membrane glycoprotein 3
lysosomal transport; intracellular protein
transport; protein metabolic process
64 2.40 PNLIP Pancreatic triacylglycerol
lipase
hydrolase activity, acting on ester bonds lipid metabolic process
65 2.37 C17orf28 UPF0663 transmembrane
protein C17orf28
66 2.36 GPR137 Integral membrane protein
GPR137
67 2.35 WARS Tryptophanyl-tRNA
synthetase, cytoplasmic
aminoacyl-tRNA ligase activity protein metabolic process
68 2.34 C11orf35 Uncharacterized protein
C11orf35
69 2.34 SCML2 Sex comb on midleg-like
protein 2
DNA binding; chromatin binding;
transcription factor activity
cell cycle; nucleobase, nucleoside, nucleotide
and nucleic acid metabolic process; cell
cycle; organelle organization; establishment
or maintenance of chromatin architecture;
ectoderm development; mesoderm
development; nervous system development
70 2.33 GNL1 Guanine nucleotide-
binding protein-like 1
GTPase activity; nucleic acid binding;
receptor binding
intracellular protein transport; cell surface
receptor linked signal transduction;
intracellular signaling cascade; nucleobase,
nucleoside, nucleotide and nucleic acid
metabolic process; signal transduction
71 2.33 MORN1 MORN repeat-containing
protein 1
kinase activity cell surface receptor linked signal
transduction; signal transduction
72 2.33 TMEM149 Transmembrane protein
149
73 2.32 AK4 Adenylate kinase
isoenzyme 4, mitochondrial
kinase activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
74 2.32 TOMM34 Mitochondrial import
receptor subunit TOM34
immune system process; protein metabolic
process; response to stress
75 2.32 ZNHIT6 Zinc finger HIT domain-
containing protein 6
76 2.31 BTG1 Protein BTG1 cell cycle; intracellular signaling cascade;
signal transduction
77 2.30 GRAMD1A GRAM domain-containing
protein 1A
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78 2.30 GRIK5 Glutamate receptor,
ionotropic kainate 5
glutamate receptor activity; ligand-gated ion
channel activity
neurological system process; cation
transport; cell surface receptor linked signal
transduction; synaptic transmission; signal
transduction; cell-cell signaling
79 2.30 TDRKH Tudor and KH domain-
containing protein
hydrolase activity, acting on ester bonds;
nucleic acid binding
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
80 2.30 TGIF1 Homeobox protein TGIF1 DNA-directed RNA polymerase activity; DNA
binding; transcription factor activity
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; ectoderm
development; nervous system development
81 2.29 FAM81B Protein FAM81B
82 2.29 MRPL9 39S ribosomal protein L9,
mitochondrial
structural constituent of ribosome; nucleic
acid binding
protein metabolic process
83 2.28 ANKRD46 Ankyrin repeat domain-
containing protein 46
84 2.27 INSM1 Insulinoma-associated
protein 1
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
85 2.27 PBX1 Pre-B-cell leukemia
transcription factor 1
DNA-directed RNA polymerase activity; DNA
binding; transcription factor activity
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; ectoderm
development; mesoderm development;
nervous system development; hemopoiesis
86 2.27 TPRG1 Tumor protein p63-
regulated gene 1 protein
87 2.26 SEPT4 Septin-4 GTPase activity;structural constituent of
cytoskeleton; protein binding
mitosis; cytokinesis
88 2.25 FAM159B UPF0514 membrane
protein FAM159B
89 2.24 AKAP8 A-kinase anchor protein 8 mitosis; chromosome segregation
90 2.24 FAM83A Protein FAM83A
91 2.24 MAG Myelin-associated
glycoprotein
receptor activity; structural constituent of
myelin sheath; receptor binding
B cell mediated immunity; cell surface
receptor linked signal transduction; cell-cell
adhesion; signal transduction; ectoderm
development; nervous system development;
response to stimulus
92 2.24 SCN9A Sodium channel protein
type 9 subunit alpha
cation transmembrane transporter activity;
voltage-gated sodium channel activity;
cation channel activity
neuronal action potential propagation;
cation transport
93 2.23 ASTN1 Astrotactin-1
94 2.23 RAB7L1 Ras-related protein Rab-7
L1
GTPase activity; protein binding neurotransmitter secretion; intracellular
protein transport; exocytosis; endocytosis;
cell cycle; cell surface receptor linked signal
transduction; intracellular signaling cascade;
signal transduction
95 2.22 RASA3 Ras GTPase-activating
protein 3
protein binding; small GTPase regulator
activity
signal transduction
96 2.22 TMEM59L Transmembrane protein 59-
like
97 2.21 CACNB3 Voltage-dependent L-type
calcium channel subunit
beta-3
cation transmembrane transporter activity;
voltage-gated calcium channel activity;
cation channel activity
muscle contraction; neurotransmitter
secretion; synaptic transmission; cell-cell
signaling
98 2.21 PLCD3 1-phosphatidylinositol-4,5-
bisphosphate
phosphodiesterase delta-3
hydrolase activity, acting on ester bonds;
calcium ion binding
cell surface receptor linked signal
transduction; lipid metabolic process; signal
transduction
99 2.21 PLCH1 1-phosphatidylinositol-4,5-
bisphosphate
phosphodiesterase eta-1
hydrolase activity, acting on ester bonds;
calcium ion binding; receptor binding; small
GTPase regulator activity; guanyl-nucleotide
exchange factor activity
cell surface receptor linked signal
transduction; intracellular signaling cascade;
lipid metabolic process; signal transduction
100 2.21 TULP1 Tubby-related protein 1 visual perception; sensory perception;
ectoderm development; nervous system
development
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expression of 13 genes involved in cell adhesion (Table
2) among cancer cells co-cultured with the CAFs. As
much as 10 of them are involved in developmental pro-
cesses as well. These genes seem to be particularly sig-
nificant because the cell adhesion is responsible for
tumour progression and metastasis, detachment from
the primary tumour and spreading to the circulatory
system. Moreover, the up-regulated genes responsible
for adhesion are by rule involved in angiogenesis and
lymphangiogenesis. For example, the vascular cell adhe-
sion molecule-1 (VCAM-1) up-regulated in cancer cells
grown as a co-culture with CAFs may be involved in
tumor progression and metastasis particularly via lym-
phangiogenesis promotion [37,38]. It also has previously
been demonstrated that the VCAM-1 plays a crucial
role in the endothelial-carcinoma cell adhesion [38].
The study also revealed an up-regulation of desmopla-
kin (DSP), which is a key component of cellular adhe-
sion junctions known as desmosomes. These junctions
are found at contact sites between endothelial cells that
form capillaries, thus DSP play a role in de novo capil-
lary formation and branching during tumourigenesis,
embryonic development and cardiovascular development
[39]. Moreover, desmoplakin isoform 2 was only
detected in tumours associated with a poor clinical out-
come. It may suggest its potentially specific function in
the regulation of cancer cells proliferation, differentia-
tion, invasion and metastasis [40,41].
Moreover, desmosomes may also be important in the
epithelium-mesenchymal transition (EMT). The epithe-
lium-mesenchymal transition is an indispensable
mechanism for morphogenesis during embryonic devel-
opment, and is implicated in conversion of early-stage
tumours into invasive cancers. During EMT, epithelial
cells undergo changes in morphology and acquire the
migratory and invasive characteristics of mesenchymal
cells [30]. EMT is also promoted by the FOXQ1,
another up-regulated gene in cancer cells grown under
co-culture conditions with the CAFs [42]. It also
increases expression of several junction proteins pro-
moting cancer cells to gain the stem-cell-like properties
and ensuring resistance to apoptosis [42-44]. Moreover,
the down regulation of keratin 20 (Table 3) in cancer
cells following the co-culture with the CAFs may indi-
cate the EMT induction [45,46].
Interestingly, another up-regulated gene in cancer cells
grown with the CAFs, which contributes to cancer inva-
sion is myelin-associated glycoprotein (MAG) that binds
to the oncogenic glycoprotein MUC1 [47]. Swanson et
al. [47] described an interaction between the MUC1 and
the MAG in cancers that invade perineurally, including
prostate, salivary, and breast carcinomas. Furthermore,
breast cancers may metastasize to the brain where the
MAG is abundantly expressed. Interactions between the
MUC1 and the MAG have not fully been defined yet.
We confirmed the MUC1 expression in all of the exam-
ined cell lines (Figure 6). Thus, based on our own
Table 2 Up-regulated genes in cancer cells grown as a co-culture with CAFs (Continued)
101 2.20 EFCAB6 EF-hand calcium-binding
domain-containing protein
6;EFCAB6
calcium ion binding; receptor binding;
calmodulin binding; enzyme regulator
activity
cation transport; cell cycle;signal
transduction; cell cycle; signal transduction
102 2.19 PTPN6 Tyrosine-protein
phosphatase non-receptor
type 6
hydrolase activity, acting on ester bonds;
phosphatase activity; receptor activity
immune system process; intracellular protein
transport; mitosis; cell surface receptor linked
signal transduction; intracellular signaling
cascade; cell-matrix adhesion; cell-cell
adhesion; protein metabolic process;
cytokinesis; cell motion; signal transduction;
nervous system development; cellular
glucose homeostasis
103 2.18 GPR155 Integral membrane protein
GPR155
receptor activity
104 2.18 PSPN Persephin receptor binding neurological system process; cell surface
receptor linked signal transduction; cell-cell
signaling; signal transduction; ectoderm
development; nervous system development
105 2.18 STAM2 Signal transducing adapter
molecule 2
transmembrane transporter activity; protein
binding; kinase activator activity; kinase
regulator activity
lysosomal transport; intracellular protein
transport; endocytosis; intracellular signaling
cascade; signal transduction
106 2.17 AGXT2L2 Alanine–glyoxylate
aminotransferase 2-like 2
transaminase activity visual perception; sensory perception;
vitamin biosynthetic process; cellular amino
acid and derivative metabolic process
The list of up-regulated genes in cancer cells grown as a co-culture with carcinoma-associated fibroblasts (CAFs). Gene ID, name, molecular functiona n d
biological process are listed according to the Panther Database classification www.pantherdb.org. The analyzed genes were significantly up-regulated at the level
of p < 0.05, fold change > 2.0.
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No Fold
change
Gene ID Gene name Molecular function Biological process
1 2.17 EPS8L1 Epidermal growth factor receptor
kinase substrate 8-like protein 1
intracellular signaling cascade; cell
motion; signal transduction
2 2.17 OR4X1 Olfactory receptor 4X1
3 2.18 C2orf61 Uncharacterized protein C2orf61
4 2.18 DSN1 Kinetochore-associated protein
DSN1 homolog
5 2.18 PFAS Phosphoribosylformylglycinamidine
synthase
ligase activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
6 2.18 SLC5A2 Sodium/glucose cotransporter 2 carbohydrate transmembrane
transporter activity; cation
transmembrane transporter activity
cation transport; extracellular transport;
amino acid transport; carbohydrate
metabolic process; cellular amino acid
and derivative metabolic process
7 2.18 TMEM138 Transmembrane protein 138
8 2.19 FOLR1 Folate receptor alpha receptor activity;transmembrane
transporter activity
vitamin transport
9 2.19 MFN2 Mitofusin-2 hydrolase activity, acting on ester
bonds; phosphatase activity
intracellular protein transport; organelle
organization; mitochondrion
organization
10 2.19 NDRG3 Protein NDRG3
11 2.19 UNC13D Protein unc-13 homolog D intracellular protein transport; exocytosis
12 2.20 GOLPH3 Golgi phosphoprotein 3
13 2.20 SLC22A13 Solute carrier family 22 member 13 ATPase activity, coupled to
transmembrane movement of
substances; ligase activity; carbohydrate
transmembrane transporter activity;
cation transmembrane transporter
activity
cation transport; anion transport;
extracellular transport; carbohydrate
transport; carbohydrate metabolic
process
14 2.20 USP54 Inactive ubiquitin carboxyl-terminal
hydrolase 54
ubiquitin-protein ligase activity protein metabolic process
15 2.22 NMI N-myc-interactor DNA binding; transcription factor
activity; transcription cofactor activity
response to interferon-gamma;
intracellular signaling cascade; signal
transduction; cellular defense response
16 2.22 PDCD1 Programmed cell death protein 1
17 2.22 SNRPN Small nuclear ribonucleoprotein-
associated protein N
RNA splicing factor activity,
transesterification mechanism; RNA
binding
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
18 2.23 SPSB1 SPRY domain-containing SOCS box
protein 1
19 2.24 ADAMTS15 A disintegrin and metalloproteinase
with thrombospondin motifs 15
peptidase activity; protein binding;
peptidase inhibitor activity
fertilization; signal transduction; cell-
matrix adhesion; cell-cell adhesion;
protein metabolic process; signal
transduction; ectoderm development;
mesoderm development; skeletal system
development; angiogenesis; nervous
system development; muscle organ
development
20 2.24 MTRF1L Peptide chain release factor 1-like,
mitochondrial
translation factor activity, nucleic acid
binding; translation release factor
activity
protein metabolic process
21 2.24 TOMM7 Mitochondrial import receptor
subunit TOM7 homolog
transmembrane transporter activity intracellular protein transport
22 2.25 ATG7 Autophagy-related protein 7 ligase activity intracellular signaling cascade; coenzyme
metabolic process; protein metabolic
process; signal transduction
23 2.25 C19orf52 Uncharacterized protein C19orf52
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24 2.25 USF2 Upstream stimulatory factor 2 DNA binding; transcription factor activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; lipid
metabolic process
25 2.26 POGK Pogo transposable element with
KRAB domain
DNA binding nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process;
ectoderm development; nervous system
development
26 2.26 ZNF804B Zinc finger protein 804B
27 2.27 CD274 Programmed cell death 1 ligand 1 ubiquitin-protein ligase activity; receptor
activity; DNA binding; receptor binding;
transcription factor activity; transcription
cofactor activity
immune system process;
neurotransmitter secretion; intracellular
protein transport; exocytosis; signal
transduction; synaptic transmission;
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; protein
metabolic process; cell-cell signaling;
organelle organization; establishment or
maintenance of chromatin architecture;
mesoderm development; mammary
gland development; response to stress;
cellular defense response
28 2.27 FAM132B Protein FAM132B
29 2.27 STK32C Serine/threonine-protein kinase 32
C
kinase activity cell cycle; intracellular signaling cascade;
protein metabolic process; cell cycle;
signal transduction
30 2.28 CADM4 Cell adhesion molecule 4 receptor activity
31 2.28 GLIPR2 Golgi-associated plant
pathogenesis-related protein 1
immune system process
32 2.28 GPR160 Probable G-protein coupled
receptor 160
33 2.29 GALNT2 Polypeptide N-
acetylgalactosaminyltransferase 2
soluble form
transferase activity, transferring glycosyl
groups
carbohydrate metabolic process; protein
metabolic process
34 2.29 KRT20 Keratin, type I cytoskeletal 20 structural constituent of cytoskeleton cellular component morphogenesis;
cellular component morphogenesis;
ectoderm development; cellular
component morphogenesis
35 2.29 PTPN6 Tyrosine-protein phosphatase non-
receptor type 6
hydrolase activity, acting on ester
bonds; phosphatase activity; receptor
activity
immune system process; intracellular
protein transport; mitosis; cell surface
receptor linked signal transduction;
intracellular signaling cascade; cell-matrix
adhesion; cell-cell adhesion; protein
metabolic process; cytokinesis; cell
motion; mitosis; signal transduction;
nervous system development; cellular
glucose homeostasis
36 2.29 SOHLH1 Spermatogenesis- and oogenesis-
specific basic helix-loop-helix-
containing protein 1
37 2.31 CENPM Centromere protein M
38 2.31 HPCAL1 Hippocalcin-like protein 1 calcium ion binding; calmodulin
binding; small GTPase regulator activity
visual perception; sensory perception;
cell surface receptor linked signal
transduction; signal transduction
39 2.31 TMEM81 Transmembrane protein 81
40 2.32 HOXA1 Homeobox protein Hox-A1 DNA binding; transcription factor activity female gamete generation; nucleobase,
nucleoside, nucleotide and nucleic acid
metabolic process; segment
specification; ectoderm development;
gut mesoderm development; embryonic
development; skeletal system
development; angiogenesis; nervous
system development; muscle organ
development
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41 2.32 SMO Smoothened homolog G-protein coupled receptor activity;
receptor binding
cell surface receptor linked signal
transduction; cell-cell signaling
42 2.33 LAMP2 Lysosome-associated membrane
glycoprotein 2
lysosomal transport; intracellular protein
transport; protein metabolic process
43 2.33 RNF121 RING finger protein 121 ubiquitin-protein ligase activity protein metabolic process
44 2.34 PLA2G2E Group IIE secretory phospholipase
A2
hydrolase activity, acting on ester bonds signal transduction; lipid metabolic
process; signal transduction
45 2.34 POU6F2 POU domain, class 6, transcription
factor 2
DNA binding; transcription factor activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
46 2.34 PPP2R4 Serine/threonine-protein
phosphatase 2A regulatory subunit
B’
protein binding;phosphatase activator
activity; phosphatase regulator activity
protein metabolic process
47 2.34 STX5 Syntaxin-5 SNAP receptor activity neurotransmitter secretion; intracellular
protein transport; exocytosis;
endocytosis; synaptic transmission; cell-
cell signaling
48 2.35 DMC1 Meiotic recombination protein
DMC1/LIM15 homolog
hydrolase activity; DNA binding immune system process; meiosis;
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; meiosis;
response to stress
49 2.35 ERRFI1 ERBB receptor feedback inhibitor 1 signal transduction;signal transduction
50 2.36 TSPYL4 Testis-specific Y-encoded-like
protein 4
protein binding; phosphatase inhibitor
activity; phosphatase regulator activity
apoptosis; cell cycle; nucleobase,
nucleoside, nucleotide and nucleic acid
metabolic process; protein metabolic
process; cell cycle; organelle
organization; establishment or
maintenance of chromatin architecture
51 2.37 USF1 Upstream stimulatory factor 1 DNA binding; transcription factor activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; lipid
metabolic process
52 2.40 ARFGAP3 ADP-ribosylation factor GTPase-
activating protein 3
nucleic acid binding; protein binding;
small GTPase regulator activity
cell surface receptor linked signal
transduction; cell adhesion
53 2.40 CNBP Cellular nucleic acid-binding
protein
nucleic acid binding nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; lipid
metabolic process
54 2.40 NKD1 Protein naked cuticle homolog 1
55 2.41 MRPL51 39S ribosomal protein L51,
mitochondrial;
structural constituent of ribosome;
nucleic acid binding
protein metabolic process
56 2.41 OPRK1 Kappa-type opioid receptor G-protein coupled receptor activity sensory perception; cell surface receptor
linked signal transduction; synaptic
transmission; cell motion; signal
transduction; cell-cell signaling
57 2.41 PTX3 Pentraxin-related protein PTX3 immune response; response to stress;
defense response to bacterium
58 2.42 GPRC5B G-protein coupled receptor family
C group 5 member B
G-protein coupled receptor activity cell surface receptor linked signal
transduction; signal transduction
59 2.42 NGLY1 Peptide-N(4)-(N-acetyl-beta-
glucosaminyl)asparagine amidase
hydrolase activity protein metabolic process
60 2.43 CAPN12 Calpain-12 peptidase activity; calcium ion binding;
calmodulin binding; calcium-dependent
phospholipid binding
induction of apoptosis; intracellular
signaling cascade; protein metabolic
process; signal transduction
61 2.43 POLD1 DNA polymerase delta catalytic
subunit
DNA-directed DNA polymerase activity;
hydrolase activity, acting on ester
bonds; nucleic acid binding
cell cycle; nucleobase, nucleoside,
nucleotide and nucleic acid metabolic
process; cell cycle
62 2.44 TBC1D8 TBC1 domain family member 8 hydrolase activity; protein binding; small
GTPase regulator activity
intracellular protein transport; exocytosis;
cellular component morphogenesis
63 2.45 DHRS11 Dehydrogenase/reductase SDR
family member 11
oxidoreductase activity visual perception; sensory perception;
lipid metabolic process
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Page 17 of 22Table 3 Down-regulated genes in cancer cells grown as a co-culture with CAFs (Continued)
64 2.46 LZTR1 Leucine-zipper-like transcriptional
regulator 1
structural constituent of cytoskeleton;
DNA binding; chromatin binding;
protein binding; small GTPase regulator
activity; transcription factor activity
spermatogenesis; immune system
process; intracellular protein transport;
vesicle-mediated transport; cell cycle;
nitrogen compound metabolic process;
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; protein
metabolic process
65 2.46 OR6V1 Olfactory receptor 6 V1
66 2.47 C12orf65 Uncharacterized protein C12orf65 translation factor activity, nucleic acid
binding; translation release factor
activity
protein metabolic process
67 2.47 C2orf56 Protein midA homolog,
mitochondrial
68 2.47 RBM42 RNA-binding protein 42 RNA splicing factor activity,
transesterification mechanism; DNA
binding; RNA binding
spermatogenesis; neurological system
process; cell cycle; nucleobase,
nucleoside, nucleotide and nucleic acid
metabolic process; protein metabolic
process; ectoderm development; nervous
system development
69 2.48 DPM2 Dolichol phosphate-mannose
biosynthesis regulatory protein
70 2.48 TDRD12 Tudor domain-containing protein
12
RNA helicase activity; translation factor
activity, nucleic acid binding; translation
initiation factor activity
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; protein
metabolic process
71 2.53 CCDC85B Coiled-coil domain-containing
protein 85B
72 2.54 MATN1 Cartilage matrix protein extracellular matrix structural constituent immune system process; sensory
perception of sound;sensory perception;
signal transduction; cell-cell adhesion;
cellular component morphogenesis;
mesoderm development; skeletal system
development; blood coagulation
73 2.55 FLYWCH1 FLYWCH-type zinc finger-containing
protein 1
74 2.55 PLA2G2D Group IID secretory phospholipase
A2
hydrolase activity, acting on ester bonds signal transduction; lipid metabolic
process; signal transduction
75 2.56 TMEM38A Trimeric intracellular cation channel
type A
76 2.58 RGS11 Regulator of G-protein signaling 11 protein binding;small GTPase regulator
activity
cell surface receptor linked signal
transduction; signal transduction; dorsal/
ventral axis specification
77 2.61 BAHD1 Bromo adjacent homology domain-
containing 1 protein
DNA binding nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
78 2.67 CHD5 Chromodomain-helicase-DNA-
binding protein 5
DNA helicase activity; nucleic acid
binding
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process; organelle
organization; establishment or
maintenance of chromatin architecture
79 2.67 CHD5 Tryptophan-rich protein; structural constituent of ribosome;
nucleic acid binding
protein metabolic process
80 2.67 CYP39A1 Cytochrome P450 39A1 oxidoreductase activity respiratory electron transport chain; lipid
metabolic process
81 2.68 SUDS3 Sin3 histone deacetylase
corepressor complex component
SDS3
cell cycle
82 2.69 C16orf62 UPF0505 protein C16orf62
83 2.69 FLOT2 Flotillin-2 intracellular protein transport; vesicle-
mediated transport
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Page 18 of 22observations and those of Swanson et al. [47], we sup-
pose that the MAG up-regulation in cancer cells grown
with the CAFs and its binding to the MUC1 may contri-
bute to the adhesion between tumour cells and Schwann
cells promoting metastasis to the nervous system.
We also found a down-regulation of 5 key genes asso-
ciated with adhesion. Subject literature suggests 3 of
them play a role in cancer development. The down-reg-
ulation of these genes is associated with poor prognosis
and cancer metastases. One of these genes is the
ADAMTS15 (a disintegrin and metalloproteinase with
thrombospondin motif 15) which is an anti-angiogenic
factor [48]. Our study also revealed a down-regulation
of the CADM4. Nagata et al. [49] found decrease in the
CADM4 expression in most of renal cell carcinomas
and the cancer cell lines. Moreover, the CADM4 expres-
sion was decreased in carcinomas with vascular infiltra-
tion, suggesting that loss of the CADM4 is involved in
tumour angiogenesis and invasion. We have also found
a down-regulation of the MATN1 gene which has been
defined an angiogenesis inhibitor [50].
In the current study we showed a significant over-
manifestation of genes involved in the oxytocin receptor
mediated signaling pathway, the thyrotropin-releasing
hormone receptor signaling, the Beta 2 and Beta1 adre-
nergic receptor signaling, and the histamine H1 receptor
mediated signaling in cancer cells grown with the CAFs.
Entschladen et al. [51] described the role of
Table 3 Down-regulated genes in cancer cells grown as a co-culture with CAFs (Continued)
84 2.69 NINJ1 Ninjurin-1 neurological system process; cell
adhesion; cell adhesion; ectoderm
development; nervous system
development
85 2.70 FAM84A Protein FAM84A
86 2.71 PAF1 RNA polymerase II-associated factor
1 homolog
87 2.71 PAF1 Peroxisome assembly factor 1 protein metabolic process
88 2.77 POLR2F DNA-directed RNA polymerases I, II,
and III subunit
DNA-directed RNA polymerase activity;
nucleic acid binding
nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
89 2.78 C12orf34 Uncharacterized protein C12orf34
90 2.80 GGT6 Gamma-glutamyltransferase 6 light
chain
acyltransferase activity; peptidase activity cellular amino acid and derivative
metabolic process; protein metabolic
process
91 2.83 TSC22D4 TSC22 domain family protein 4 DNA binding; transcription factor activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
92 2.84 CLRN2 Clarin-2
93 2.92 KCNS1 Potassium voltage-gated channel
subfamily S member 1
cation transmembrane transporter
activity; voltage-gated potassium
channel activity; cation channel activity
muscle contraction; blood circulation;
neuronal action potential propagation;
cation transport; signal transduction;
synaptic transmission; signal
transduction; cell-cell signaling
94 2.94 OR51T1 Olfactory receptor 51 T1
95 2.96 OR51I1 Olfactory receptor 51I1
96 3.01 ZNF135 Zinc finger protein 135 DNA binding;transcription factor activity nucleobase, nucleoside, nucleotide and
nucleic acid metabolic process
97 3.03 QDPR Dihydropteridine reductase oxidoreductase activity cellular amino acid and derivative
metabolic process
98 3.11 C9 Complement component C9b peptidase activity; receptor activity complement activation; signal
transduction; cell-cell adhesion; protein
metabolic process; signal transduction;
response to stimulus
99 3.16 VDAC1 Voltage-dependent anion-selective
channel protein 1
voltage-gated ion channel activity; anion
channel activity
anion transport
100 3.85 FDX1L Adrenodoxin-like protein,
mitochondrial
oxidoreductase activity respiratory electron transport chain;
ferredoxin metabolic process; vitamin
metabolic process; lipid metabolic
process; protein metabolic process
The list of down-regulated genes in cancer cells grown as a co-culture with carcinoma-associated fibroblasts (CAFs). Gene ID, name, molecular function and
biological process are listed according to the Panther Database classification www.pantherdb.org. The analyzed genes were significantly down-regulated at the
level of p < 0.05, fold change > 2.0.
Król et al. BMC Veterinary Research 2012, 8:35
http://www.biomedcentral.com/1746-6148/8/35
Page 19 of 22neurotransmitters in cancer progression and metastasis.
They found that similarly to chemokines, neurotransmit-
ters are regulators of cell migration. Sadly though, we
noticed that only a few results are available on the
expression of neurotransmitter receptors in tumour tis-
sues. Among them the best understood is the role of
catecholamines in carcinogenesis and tumour progres-
sion. These are the stress hormones, whereas stress in
turn is a major risk factor for the development of can-
cer. Norepinephrine has been shown to strongly induce
the migration of tumor cells [52,53], whereas epinephr-
ine was found a modulator for the carcinogenesis in the
lung [54].
An interesting gene in cancer cells grown as a co-cul-
ture with the CAFs is the up-regulated protocadherin 19
(PCDH19) (Table 2). Up-to-date there is no information
available on the involvement of this gene in tumor pro-
gression or metastasis. However, a PCDH19 mutation
was found to be responsible for epilepsy and mental
retardation confined to females (EFMR) [55]. There has
been an on-going debate about the relationship between
epilepsy and cancer. It has been hypothesized that the
incidence of cancer is increased in people with epilepsy
owing to the cancer promotion by antiepileptic drugs
[56]. Perhaps the increased risk of cancer in epileptic
patients is caused by the PCDH19 mutation and over-
Figure 5 Selected genes expression assessed using real-time qPCR. Expression of randomly selected genes in canine mammary cancer lines
growing as a monoculture and co-culture with CAFs. The changes in gene expression differed highly significant (p < 0.001, N=3).
Figure 6 MUC1 expression in canine mammary cancer cell lines. MUC1 expression (brown color) in canine mammary cancer cell lines: A.
CMT-U27, B. CMT-U309, C. P114, D. CMT-W1 and E. CMT-W2. The pictures were obtained using Olympus BX60 microscope (at the magnification
of 200×).
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Page 20 of 22expression, not however related to drugs toxicity. This
hypothesis requires further studies.
Conclusions
The results of the current study showed that the co-cul-
ture of cancer cells and the CAFs caused significant
changes in expression of genes involved in adhesion,
angiogenesis and the EMT that take part in develop-
mental processes.
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